112 ANALYSIS OF A BROAD SPECTRUM OF URINARY AND SERUM BIOMARKERS IN A LARGE COHORT OF PATIENTS WITH EARLY OA OF HIP AND/OR KNEE (CHECK): THE FIRST RESULTS  by van Spil, W.E. et al.
Osteoarthritis and Cartilage Vol. 17, Supplement 1 S67
Methods: Blood samples were collected from patients with
rheumatoid arthritis (n=33) and healthy controls (n=33), serum
was harvested and stored at -20°C until testing. Aggrecan frag-
ments carrying the aggrecanase-derived neo-epitope NITEGE373
was determined using the G1-NITEGE373 ELISA, correspond-
ing fragments carrying the 374ARGSV neo-epitope using the
374ARGSV-G2 ELISA, and ﬁnally total aggrecan was determined
using the G1/G2 ELISA.
Results: We determined the concentration of G1-373NITEGE
aggrecan fragments in human serum and found 989 ng/ml ±
238 ng/ml (mean ± SD) and 310 ng/ml ± 42 ng/ml in patients
with RA and controls, respectively. This corresponds to a 3-fold
increase, which was highly signiﬁcant (p=0.004). In parallel, we
determined the concentration of the 374ARGSV-G2 fragments,
which also is derived from aggrecanase-cleavage of aggrecan,
however, no difference between RA and controls was detected.
Finally, circulating levels of total aggrecan, as determined by
the G1/G2 ELISA, was suppressed in RA patients vs controls
(p=0.0003), whereas MMP-derived fragments determined in the
342FFGVG-G2 ELISA was similar in the two groups.
Conclusions: We conclude, that whereas the total circulating
levels of aggrecan fragments carrying the G1 and/or G2 do-
mains is suppressed in RA patients, then the serum concentration
of the aggrecanase-derived aggrecan neo-epitopes, but not the
MMP-mediated, are elevated in in patients with RA. Circulating
aggrecanase-mediated aggrecan fragments may be more sensi-
tive than MMP-derived fragments to detect cartilage damage in
RA.
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SERUM cartilage oligomeric matrix protein
CONCENTRATION CAN PREDICT SUBSEQUENT MRI
CHANGES OF EARLY KNEE OA
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R. Bobba2, J.D. Adachi2, F. Jabbary2
1McMaster Univ., Hamilton, ON, Canada; 2Hamilton Hlth. Care,
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Purpose: Serum measures of cartilage oligomeric matrix protein
(COMP), a marker of cartilage degradation, may be a promising
tool for evaluating OA severity or perhaps predicting disease
progression. Here we use COMP to predict the changes of early
knee OA detected by peripheral MRI during a two year follow up
study.
Methods: 33 patients (8 men and 25 women) aged 45-65 years
with chronic (>2 month duration) knee pain and diagnosed with
early knee osteoarthritis were chosen and followed for 24 months.
A blood sample was obtained at baseline and the serum concen-
tration of COMP was determined by immunoassay. MRI scans (3D
Gradient Echo for cartilage evaluation) for the symptomatic knee
were performed at baseline, 6 months, 12 months and 24 months
later. A trained radiologist semiquantitatively graded cartilage on a
scale of 0-4 in each of the medial tibia, lateral tibia, medial femur
and lateral femur. The maximum score that can be obtained is 24.
The baseline MRI cartilage score of all patients is ranged from 7
to 14.
Results: A signiﬁcant, positive regression was found between
baseline serum COMP concentration and the changes of MRI
cartilage scores over 24 months (R2=44.5%, P<0.001).
Conclusions: These results suggest that higher COMP at base-
line in patients with early OA could reﬂect increased cartilage
degeneration over time relative to those with lower COMP levels.
These ﬁndings support the hypothesis that a marker of cartilage
degradation may predict future cartilage degeneration.
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Purpose: Biomarkers to diagnose OA in an early stage and/or
to predict its course would be of great value. Therefore, we se-
lected a broad spectrum of commercially available serum and
urinary biomarkers representative of cartilage, bone and syn-
ovium metabolism for evaluation in the Cohort Hip & Cohort Knee
(CHECK). This cohort consists of 1002 participants with pain
and/or stiffness of knee and/or hip, aged 45-65 yrs, and who had
never or no longer than 6 months before visited their physician
for these symptoms for the ﬁrst time. Hip and knee radiographs
as well as clinical parameters and multiple questionnaires are
evaluated at regular intervals. Furthermore, blood (plasma and
serum; s) and urine (u) samples (multiple aliquots of all three)
are collected at 0, 2, 5, 8, and 10 yrs. Samples are obtained in
10 medical centers and processed in the same central laboratory,
all according to strict protocols. Biomarker measurement in these
samples provides a unique opportunity to study the diagnostic
and prognostic properties of biomarkers in early-stage OA. Base-
line biomarker measurement has recently been completed. The
data set is huge, speciﬁcally in combination with all patient char-
acteristics and longitudinal radiographic and clinical data. Before
relations are calculated we have to be sure about the quality of
the biomarker data set. This abstract covers this issue.
Methods: Baseline samples were thawed for the ﬁrst time.
Commercially available ELISA assays were performed to mea-
sure uCTX-II, uCTX-I (ImmunoDiagnostic Systems Ltd.), uNTX-I
(Wampole Laboratories), sCOMP (Anamar Med AB), sOC (IDS),
sHA (Corgenix Inc.), sPIIANP (Millipore Corp.), sCS846, and
sC1,2C (IBEX) and RIA assays for sPINP and sPIIINP (Orion
Diagnostica). All kits were purchased without commercial involve-
ment and for each biomarker kits were from the same badge.
A serum and urine pool were created from several OA patients and
aliquoted. At each of the assay days an aliquot was thawed and
included at multiple places in the assay plates. Each biomarker
was measured in all samples by the same technician in 8 days in
a period of 6 wks using 14 kits.
Results: Quality control as was performed by using a randomly
distributed pool sample, controls as supplied by manufacturers,
and blank samples in-between patient samples was unremarkable,
except for the COMP assay. The COMP assay’s pool sample
showed a remarkably variable biomarker concentration within and
between assay plates.
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When biomarker concentrations of all patient samples were plot-
ted in chronological order of assaying, it appeared that there
was a sufﬁcient window of variation within a positively skewed
distribution. In general there was no evident variation over time
and between assays, except for two remarkable observations:
For the sCOMP assay there was a clear difference in measured
biomarker concentrations between the ﬁrst 6 kits and last 8 kits.
In the ﬁrst kits measured biomarker concentrations were a 10-fold
higher and showed signiﬁcantly more variation than in the last
kits. For the sC1,2C and sCS846 assays, there was a signiﬁcant
negative correlation between the measured biomarker concentra-
tion and sample order (chronologic/position) in the assay plates,
repeatedly found for each of the assay plates.
Conclusions: Reliable biomarker measurement in this large sam-
ple set seems possible for the majority of the studied biomarkers.
However, despite attempts to minimize variation, there are some
striking challenges, presumably technical in nature. The remark-
able observations in the sCOMP assay, and the sC1,2C and
sCS846 assays need further evaluation (as is presently ongoing)
before correlations with the clinical and radiographic data sets can
be made.
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ANALYSIS OF 31 BIOMARKERS AND BIOMARKER
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Purpose: 1) To determine the association of 31 biomarkers with
pre-radiographic and radiographic symptomatic knee OA com-
pared to symptomatic controls; 2) to determine if latent biomarker
factors determined by principal components based factor analy-
sis (PC-FA) are better able to distinguish OA stage compared to
individual biomarkers. PC-FA, in addition to revealing potential un-
derlying factors, may be useful to overcome problems of multiple
comparisons and may help stabilize variance.
Methods: 255 subjects, 40-79 years, with knee pain were as-
sembled, stratiﬁed by age decade and gender, in a cross-sectional
population-based study and evaluated with MRI, xray and biomark-
ers. MR cartilage (MRC) defects (score 0-4) and x-rays (Kellgren-
Lawrence [KL] grade 0-4) were read blinded. Subjects were
classiﬁed as No OA (NOA) (KL<2, MRC=0), Pre-Radiographic
OA (PROA) (KL<2, MRC≥1) or Radiographic OA (ROA) (KL≥2,
MRC≥1). Serum levels of matrix metalloproteinases (MMPs) 1, 3
and 9, tissue inhibitor of MMP, interleukins 1a, 1b, 4, 6, 7, 8, 10,
17A, tumor necrosis factor, c-telopeptide of type I collagen (CTX-I),
adiponectin, resistin, eotaxin, C-reactive protein, hyaluronic acid
(HA) and other cytokines were evaluated. PC-FA was performed
using individual biomarkers and ratios of markers previously mea-
sured, including urine c-telopeptide of type II collagen (uCTX-II),
urine and serum type II and types I and II collagen cleavage
neoepitopes (C2C and C1,2C respectively), c-propeptide of type
II procollagen (CPII), 846 epitope, and urine n-telopeptide of type
I collagen (uNTX-I). Multicategory logistic regression (adjusted for
age, sex and BMI) was used to evaluate the association of OA cat-
egory with each log transformed biomarker, biomarker ratio, and
biomarker factor, incorporating stratum sampling weights. Stan-
dardized (i.e. per standard deviation change) odds ratios (ORs)
were reported to enable comparison of the ORs across biomarker
variables.
Results: Signiﬁcant associations with PROA vs NOA were seen
for MMP-9 (OR 1.60, 95% CI 1.00-2.57), uC2C (OR 2.34, 95% CI
1.34-4.09), uC1,2C (OR 1.99, 95% CI 1.24-3.19), and uC2C/sCPII
ratio (OR 2.41, 95% CI 1.33-4.37). Risk of ROA vs NOA was
signiﬁcantly increased for uCTX-II (OR 2.97, 95% CI 1.45-6.08),
uC2C (OR 2.28, 95% CI 1.23-4.22), uC1,2C (OR 2.08, 95%
CI 1.21-3.56), uCTX-II/sCPII (OR 2.62, 95% CI 1.35-5.06) and
uC2C/sCPII (OR 2.55, 95% CI 1.32-4.95). PC-FA identiﬁed 4 clin-
ically interpretable factors, of which one factor (determined largely
by uCTX-II, uC2C, uNTX-I, CTX-I, uC1,2C, and HA) was signif-
icantly associated with PROA (OR 2.08, 95% CI 1.04-4.14) and
with ROA (OR 2.52, 95% CI 1.22-5.20). PC-FA with inclusion of
biomarker ratios resulted in similar ﬁndings. The strength of asso-
ciation with PROA and ROA was similar for individual biomarkers,
biomarker ratios and biomarker factors.
Conclusions: In this population-based study, several biomark-
ers were signiﬁcantly associated with PROA (MMP-9, uC2C and
uC1,2C), and with ROA (uCTX-II, uC2C, uC1,2C). Discrimination
of OA groups within this cohort was not improved using biomarker
factors (determined by factor analysis) over individual biomarkers
or biomarker ratios.
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TENASCIN-C LARGE, AN ELASTIC PROTEIN INDICATING
JOINT DISEASE/INJURY IN HUMANS & PRECLINICAL
ANIMAL MODELS
L. Patel, W. Sun, S. Glasson, K.E. Georgiadis, E.A. Morris,
P.S. Chockalingam
Wyeth Res., Cambridge, MA
Purpose: Tenascin-C (TN-C) is a modular, multifunctional,
hexabrachion-shaped, elastic extra cellular matrix (ECM) glyco-
protein with binding sites for other ECM proteins. It was discovered
originally at the myotendinous junction and later found in the os-
teotendinous junction and superﬁcial layers of articular cartilage.
It plays a major role in cell adhesion & migration, and stretches
several times its resting length due to its ﬁbronectin type (FN) III
domain. TN-C is abundantly expressed in musculoskeletal tissues
during organogenesis and embryogenesis, its expression is very
restricted in healthy tissues, and reappears as a high molecular
weight splice variant in association with wound healing, inﬂamma-
tory processes, or neoplasia. TN-C has been reported to be highly
reexpressed in cartilage in diseased/injured joints. The objective
of this study was to evaluate the potential of TN-C as a marker of
joint disease/injury.
Methods: TN-C high molecular weight variants that include FN
III A-D domains were speciﬁcally detected in synovial ﬂuid (SF)
samples by the Tenascin-C Large ELISA (IBL). Human SF from
patients with end stage osteoarthritis (OA, 28), rheumatoid arthri-
tis (RA, 8), anterior cruciate ligament rupture (ACL, 8), and
knee-healthy reference subjects (Ref, 24) from NEBH/Northland
Labs/NEBH/NDRI &Northland Labs, respectively were tested in
the assay. Joint instability surgery was performed in male cross-
bred hounds, right knee had a mini-arthrotomy and anterior cruci-
ate ligament transected (ACLT), and the contralateral limb had a
’sham’ surgery with a miniarthrotomy but no generation of instabil-
ity. At 1, 3 and 6 months post-surgery, 4-6 animals per timepoint
were euthanized, and SF collected from ACLT/sham knees. Joint
instability was induced in rats (n=4-6 per group) by medial menis-
cal surgery in one knee with the other knee as a contralateral
control. SF lavage samples collected at 1, 4, and 8 wks post
surgery.
Results: TN-C levels were signiﬁcantly elevated in SF from OA (7-
fold), RA (5-fold), and ACL (3-fold) human patients as compared to
reference individuals. There was a concomitant increase in TN-C
levels in human OA cartilage (>60-fold) as compared to non-OA
